Tidewave Bio

Executive Summary

Tidewave Bio is a preclinical-stage biotechnology company pioneering a universal, off-the-shelf cell therapy platform for solid tumors. Founded in 2021 in San Diego, the company's technology enables real-time personalization at the point of care using a patient's tumor biopsy, aiming to overcome manufacturing, logistical, and efficacy hurdles that have historically limited cell therapies in solid tumors. By developing allogeneic products that can be scaled and delivered off-the-shelf, Tidewave Bio seeks to bring cell therapy to a broader patient population. The platform is designed to address the immunosuppressive tumor microenvironment and provide durable anti-tumor responses. As a private, early-stage company without disclosed funding rounds, Tidewave Bio's progress relies on successful preclinical validation and capital infusion to advance toward clinical trials.

Upcoming Catalysts (preview)

• Q2 2026Series A or Seed Extension Financing60% success
• Q4 2026Preclinical Proof-of-Concept Data Release50% success
• H2 2026Academic or Industry Partnership Announcement40% success